What is Cognetivity Neurosciences Ltd?
It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app.
CGNSF · Verdict
Limited reward · elevated risk
CGNSF has limited near-term tailwinds — cash flow and profitability weigh on the model output.
Based on 88% data coverage
CGNSF · Verdict
-13252% free-cash-flow margin
-16386% net margin · -643% ROE
Earnings +41.1% CAGR
Model-based scoring. For information only — not financial advice.
It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.96K.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.